ClinicalTrials.gg
RecruitingNCT07192939Updated Dec 24, 2025

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

A Phase 2 interventional study of HRS-9813 capsules and HRS-9813 capsules in IPF and PPF, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。

02

Conditions studied

  • IPF and PPF
03

In context

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. was obtained to participate in the trial
  2. Patients were aged ≥21 years for PPF and ≥45 years for IPF.
  3. IPF diagnosed within 7 years before screening (including the screening period) or evidence of progressive ILD within 12 months before screening;
  4. HRCT and surgical lung or transbronchial lung cryobiopsy, when available, support the clinical diagnosis;
  5. The central HRCT reading results of PPF at screening showed that the whole lung parenchymal fibrosis was > 10%;
  6. Treatment with nintedanib or pirfenidone was discontinued at least 8 weeks before screening or was stabilized for at least 8 weeks;
  7. FVC as a percentage of normal predicted value ≥40%;
  8. DLCO SB ( corrected) as a percentage of normal predicted value ≥25%;
  9. Female subjects of must have a negative pregnancy test before the first dose of medication. And must be non-lactating. Female subjects of childbearing potential or male subjects whose partner is a female of childbearing potential agree to be infertile, have a sperm/egg donation plan, and voluntarily use highly effective (including their partner) from the time they sign ICF until 14 days after the last dose of medication, which is the end of safety follow-up.

Exclusion criteria

Exclusion Criteria:

  1. IPF cohort: i. Interstitial lung disease (ILD) of other known cause; ii. Diagnosis of sarcoidosis or any systemic disease;
  2. PPF cohort: IPF diagnosis and UIP features supported by HRCT central reading, surgical lung , or cryobiopsy pathology.
  3. The presence of emphysema of 50% or more on centrally read HRCT or the degree of emphysema greater than the degree of fibrosis on the basis of the most recent HRCT report.
  4. The presence of nonsubstantial lung disease was considered by the investigator to be likely to affect the assessment of the study.
  5. Subjects were known to have pulmonary hypertension requiring treatment with multiple medications.
  6. Active tuberculosis infection within 12 months before and/or during screening, or lower respiratory tract infection requiring antibiotic treatment within 4 weeks before and/or during screening, or evidence of active infection on clinical and laboratory tests at the screening/baseline visit.
  7. Acute exacerbations of IPF/ILD occurred within 12 weeks before and/or during screening.
  8. A history of unstable or worsening cardiac disease within 6 months before screening
  9. Uncontrolled atrial or ventricular arrhythmias or the known presence of significant left ventricular dysfunction.
  10. A cerebrovascular event leading to hospitalization had occurred within 6 months before screening
  11. Had a history of lung volume reduction surgery or transplant, were awaiting lung transplant, or were scheduled to undergo lung volume reduction surgery or transplant during the study period.
  12. Subjects with a history of within the previous 5 years, or a suspicion of malignancy on biopsy, and those for whom the possibility of malignancy could not be reasonably ruled out after additional clinical, laboratory, or other diagnostic evaluation were screened.
  13. The patients were positive for surface antigen (HBsAg) or virus antibody (HCVAb) at the time of screening. A test for antibodies to the (HIV) was not negative at screening.
  14. A history of smoking (including e-cigarettes) within 3 months before screening or an unwillingness to quit smoking during the study.
  15. Regular alcohol consumption in the 6 months before screening or an unwillingness to reduce alcohol consumption to less than 21 units during the study.
  16. He had a history of substance abuse within 6 months before screening.
  17. Pregnant or breastfeeding.
  18. Treatment with prednisone at a dose of more than 15 mg per day or another systemic at the equivalent dose was received within 4 weeks before screening and during the study.
  19. Use of an IL-6 inhibitor within 3 months before screening and planned use during the study.
  20. Disease-modifying antirheumatic drugs or a change in dose were initiated within 3 months before screening.
  21. Initiation of mycophenolate mofetil, mycophenolic acid, azathioprine, tacrolimus, methotrexate, leflunomide, or a change in the dose of the above drugs within 3 months before screening; drugs could not be started during the treatment phase.
  22. Rituximab was used 6 months before screening and was planned for the duration of the study.
  23. Participants who had used a potent inhibitor or inducer of cytochrome P450(CYP)3A4 within 4 weeks before randomization or who had to be treated with or planned to be treated with a drug ban during the study.
  24. Persons who had participated in a clinical trial of any drug or device within 1 month before screening and who had expected legacy effects of the trial treatment (at the discretion of the investigator) or who were within the follow-up period of a clinical study or the five half-lives of the trial drug before screening.
  25. Major surgery (surgery under general anesthesia) that was performed within 3 months before screening or that was planned during the study that, as assessed by the investigator, would affect the determination of the end points.
  26. Uncontrolled hypertension was present before screening or randomization.
  27. Patients with orthostatic intolerance, orthostatic hypotension, or orthostatic tachycardia, as well as patients with a previous history of these conditions, at screening or before randomization.
  28. A history of persistent or active syncope after urination/defecation, a previous known history of syncope, or a concomitant medical condition that increases the risk of syncope.
  29. , transaminase, blood routine and other abnormalities exceed the requirements during screening.
  30. An showed a heart rate of less than 55 beats per minute before screening or randomization or a of at least 500 msec or a QTcF interval of at least 450 msec before randomization.
  31. Allergy to drugs in the same class or to any component of HRS-9813.
  32. Other reasons for not participating in the study as judged by the investigator.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS-9813 capsules

    Drug: HRS-9813 capsules

  • Experimental
    Treatment group B: HRS-9813 capsules

    Drug: HRS-9813 capsules

  • Placebo comparator
    Treatment group C: HRS-9813 capsule mimetic.

    Drug: HRS-9813 capsule mimetic

Interventions

06

What researchers measure

Primary outcomes

  1. FVC as a percentage of the predicted value

    Time frame: The baseline period lasted until 26weeks after administration

Secondary outcomes

  1. The rate of change in ppFVC

    Time frame: The baseline period lasted until 26 weeks after administration

  2. Absolute change in FVC.

    Time frame: The baseline period lasted until 26 weeks after administration

  3. Changes in lung carbon monoxide diffusion capacity (DLCO SB) (hemoglobin corrected) and its percentage of the predicted value (ppDLCO SB) (hemoglobin corrected).

    Time frame: The baseline period lasted until 26 weeks after administration

  4. Proportion of subjects with an absolute decline in ppFVC (%) of ≥10% from baseline.

    Time frame: The baseline period lasted until 26 weeks after administration

  5. Proportion of subjects with acute exacerbation of pulmonary fibrosis.

    Time frame: The baseline period lasted until 26 weeks after administration

  6. Proportion of subjects with respiratory-related hospitalizations.

    Time frame: The baseline period lasted until 26 weeks after administration

  7. Proportion of subjects with pulmonary fibrosis-related hospitalizations.

    Time frame: The baseline period lasted until 26 weeks after administration

  8. All-cause mortality.

    Time frame: The baseline period lasted until 26 weeks after administration

  9. Proportion of subjects with pulmonary fibrosis disease progression.

    Time frame: The baseline period lasted until 26 weeks after administration

  10. The changes of the scores of each sub-item and the impact part of the Pulmonary fibrosis questionnaire (L-PF) were observed.

    Time frame: The baseline period lasted until 26 weeks after administration

07

Study locations

1 of 1 sites recruiting
  • Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Zuojun Xu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Sep 25, 2025
StartActual
Oct 29, 2025
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192939
Responsible party
Sponsor
First posted
Sep 25, 2025
Start date
Oct 29, 2025
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Dec 24, 2025

Study contacts

Jinrui Wang
Contact
jinrui.wang.jw207@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9813

Start the discussion